CH633370A5 - Verfahren zur bestimmung von antigenen und antikoerpern. - Google Patents
Verfahren zur bestimmung von antigenen und antikoerpern. Download PDFInfo
- Publication number
- CH633370A5 CH633370A5 CH999177A CH999177A CH633370A5 CH 633370 A5 CH633370 A5 CH 633370A5 CH 999177 A CH999177 A CH 999177A CH 999177 A CH999177 A CH 999177A CH 633370 A5 CH633370 A5 CH 633370A5
- Authority
- CH
- Switzerland
- Prior art keywords
- antibody
- antigen
- latex
- light
- reaction
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims description 82
- 102000036639 antigens Human genes 0.000 title claims description 82
- 108091007433 antigens Proteins 0.000 title claims description 82
- 238000000034 method Methods 0.000 title claims description 59
- 239000002245 particle Substances 0.000 claims description 92
- 229920000126 latex Polymers 0.000 claims description 88
- 239000004816 latex Substances 0.000 claims description 85
- 238000002835 absorbance Methods 0.000 claims description 62
- 108010049003 Fibrinogen Proteins 0.000 claims description 39
- 229940012952 fibrinogen Drugs 0.000 claims description 39
- 102000008946 Fibrinogen Human genes 0.000 claims description 38
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 239000011541 reaction mixture Substances 0.000 claims description 31
- 230000008033 biological extinction Effects 0.000 claims description 29
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 239000004793 Polystyrene Substances 0.000 claims description 23
- 229920002223 polystyrene Polymers 0.000 claims description 23
- 238000005259 measurement Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 210000002700 urine Anatomy 0.000 claims description 12
- 239000012876 carrier material Substances 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 239000011521 glass Substances 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 230000004520 agglutination Effects 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000001678 irradiating effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 101710145634 Antigen 1 Proteins 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 239000000523 sample Substances 0.000 description 54
- 239000000243 solution Substances 0.000 description 47
- 238000011088 calibration curve Methods 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 39
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 17
- 238000003127 radioimmunoassay Methods 0.000 description 16
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 15
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 15
- 102400000050 Oxytocin Human genes 0.000 description 15
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 15
- 101800000989 Oxytocin Proteins 0.000 description 15
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 15
- 229960001723 oxytocin Drugs 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- 230000035484 reaction time Effects 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 208000008423 pleurisy Diseases 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940106780 human fibrinogen Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- UZKIAJMSMKLBQE-SUPAOECSSA-N (2s,3s,4s,5r)-6-[[(8r,9s,13s,14s,16r,17r)-16,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@H]4O)C)CC2=CC=3OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O UZKIAJMSMKLBQE-SUPAOECSSA-N 0.000 description 1
- PPKMIGDPMKHNNB-UHFFFAOYSA-N 2-aminoacetic acid;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound NCC(O)=O.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O PPKMIGDPMKHNNB-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000003023 adrenocorticotropic effect Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000431 corpus luteum hormone Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052809 inorganic oxide Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940056932 lead sulfide Drugs 0.000 description 1
- 229910052981 lead sulfide Inorganic materials 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000000411 transmission spectrum Methods 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- -1 urine Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/832—Bacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/882—Staphylococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Plasma & Fusion (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP51097158A JPS5811575B2 (ja) | 1976-08-16 | 1976-08-16 | 抗原−抗体反応の測定法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH633370A5 true CH633370A5 (de) | 1982-11-30 |
Family
ID=14184754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH999177A CH633370A5 (de) | 1976-08-16 | 1977-08-16 | Verfahren zur bestimmung von antigenen und antikoerpern. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4118192A (en:Method) |
| JP (1) | JPS5811575B2 (en:Method) |
| BE (1) | BE857826A (en:Method) |
| CA (1) | CA1098822A (en:Method) |
| CH (1) | CH633370A5 (en:Method) |
| CS (1) | CS221270B2 (en:Method) |
| DD (1) | DD132149A5 (en:Method) |
| DE (1) | DE2736805C2 (en:Method) |
| FR (1) | FR2362398A1 (en:Method) |
| GB (1) | GB1545991A (en:Method) |
| HU (1) | HU176294B (en:Method) |
| NL (1) | NL184027C (en:Method) |
| SE (1) | SE445494B (en:Method) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54108695A (en) * | 1978-02-15 | 1979-08-25 | Teikoku Hormone Mfg Co Ltd | Method and device for measuring antigennantibody reaction |
| US4203724A (en) * | 1976-08-16 | 1980-05-20 | Mitsubishi Chemical Industries Limited | Method and apparatus for the measurement of antigens and antibodies |
| US4208185A (en) * | 1976-08-16 | 1980-06-17 | Mitsubishi Chemical Industries Limited | Method and apparatus for the measurement of antigens and antibodies |
| IT1087285B (it) * | 1976-11-10 | 1985-06-04 | Hoffmann La Roche | Procedimento di determinazione immunologico |
| US4411518A (en) * | 1977-09-23 | 1983-10-25 | Gamma Biologicals, Inc. | Apparatus for use in qualitative determination of immunological reactions |
| US4197088A (en) * | 1977-09-23 | 1980-04-08 | Akro-Medic Engineering, Inc. | Method for qualitative and quantitative determination of immunological reactions |
| JPS54108693A (en) * | 1978-02-14 | 1979-08-25 | Mitsubishi Chem Ind | Method and device for optically measuring antigennantibody reaction |
| JPS54109494A (en) * | 1978-02-16 | 1979-08-28 | Teikoku Hormone Mfg Co Ltd | Method of measuring antigennantibody reaction |
| JPS54139595A (en) * | 1978-04-20 | 1979-10-30 | Mitsubishi Chem Ind | Reagent for detecting antigen |
| US4205954A (en) * | 1978-05-26 | 1980-06-03 | Warner-Lambert Company | Kinetic latex agglutinometry |
| US4213764A (en) * | 1978-08-09 | 1980-07-22 | Akzona Incorporated | Method for determining immunochemical substances |
| JPS55162059A (en) * | 1979-06-05 | 1980-12-17 | Mochida Pharmaceut Co Ltd | Measuring method for antigen, antibody or their complex and measurement reagent kit |
| JPS562552A (en) * | 1979-06-14 | 1981-01-12 | Warner Lambert Co | Dynamic latex cohesin cohesion measurement method |
| JPS5639465A (en) * | 1979-09-10 | 1981-04-15 | Olympus Optical Co Ltd | Detecting method of immunological agglutination |
| DE3005417A1 (de) * | 1980-02-14 | 1981-08-20 | Behringwerke Ag, 3550 Marburg | Verfahren zur bestimmung von immunkomplexen |
| US4575484A (en) * | 1980-05-05 | 1986-03-11 | Montefiore Medical Center, Inc. | Binding assay for the detection of mycobacteria |
| JPS57182168A (en) * | 1981-05-02 | 1982-11-09 | Mitsubishi Chem Ind Ltd | Immunochemical reagent |
| JPS60128368A (ja) * | 1983-12-15 | 1985-07-09 | Olympus Optical Co Ltd | 免疫学的分析方法 |
| GB8509492D0 (en) * | 1985-04-12 | 1985-05-15 | Plessey Co Plc | Optical assay |
| US4721681A (en) * | 1985-05-14 | 1988-01-26 | Fisher Scientific Company | Immunoassay in centrifugal field with complementary particles of differing specific gravities |
| JPS62218864A (ja) * | 1986-03-20 | 1987-09-26 | Hitachi Chem Co Ltd | ヒトｃ反応性タンパクの定量法 |
| JPS62218866A (ja) * | 1986-03-20 | 1987-09-26 | Hitachi Chem Co Ltd | ヒトｃ反応性タンパク定量用試薬 |
| JPH0731112B2 (ja) * | 1986-08-11 | 1995-04-10 | 株式会社日立製作所 | 粒子状物質の検出方法およびその装置 |
| JPS6435373A (en) * | 1987-07-31 | 1989-02-06 | Fujirebio Kk | Method and device for high-sensitivity immunoassay |
| US4859612A (en) * | 1987-10-07 | 1989-08-22 | Hygeia Sciences, Inc. | Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite |
| US5202267A (en) * | 1988-04-04 | 1993-04-13 | Hygeia Sciences, Inc. | Sol capture immunoassay kit and procedure |
| US5100805A (en) * | 1989-01-26 | 1992-03-31 | Seradyn, Inc. | Quantitative immunoassay system and method for agglutination assays |
| US5198369A (en) * | 1990-04-25 | 1993-03-30 | Canon Kabushiki Kaisha | Sample measuring method using agglomeration reaction of microcarriers |
| DE4211351A1 (de) * | 1992-04-04 | 1993-10-07 | Behringwerke Ag | Verfahren zur Analyse partikelverstärkter Agglutinationsreaktionen auf Zentrifugalanalysatoren durch Bestimmung der Trübungsaufhellung |
| DE69624920T2 (de) * | 1996-09-27 | 2003-09-18 | Inverness Medical Switzerland Gmbh, Zug | Testreagentien und Testvorrichtungen |
| DE19858188A1 (de) * | 1998-12-17 | 2000-07-06 | Centeon Pharma Gmbh | Verfahren zum Auflösen von Albuminflocken in einer Flüssigkeit sowie Einrichtung zur Durchführung des Verfahrens |
| JP3756007B2 (ja) | 1999-01-28 | 2006-03-15 | 富士写真フイルム株式会社 | 乾式分析方法及び乾式分析要素 |
| EP1607742B1 (en) * | 2003-03-24 | 2011-11-23 | Mitsubishi Chemical Medience Corporation | Latex reagent for adiponectin analysis and method of adiponectin analysis |
| EP2037272B1 (en) | 2006-06-30 | 2013-09-18 | JNC Corporation | Kit for detection/quantification of analyte, and method for detection/quantification of analyte |
| JP5193228B2 (ja) | 2007-12-28 | 2013-05-08 | オーソ・クリニカル・ダイアグノスティックス株式会社 | 検出対象の検出方法及び定量方法 |
| EP2246701B1 (en) | 2007-12-28 | 2016-12-14 | Ortho-clinical Diagnostics Kabushiki Kaisha | Method of detecting substance to be detected and method of determination |
| CA2763856C (en) | 2009-05-29 | 2014-07-08 | Ortho-Clinical Diagnostics Kabushiki Kaisha | Signal transduction by aggregation inhibition developed on a solid carrier |
| WO2011057198A1 (en) | 2009-11-09 | 2011-05-12 | Carson Cantwell G | Vaccine testing system |
| JP6563681B2 (ja) * | 2015-05-08 | 2019-08-21 | シスメックス株式会社 | 検体分析装置、血液凝固分析装置、検体分析方法、及びコンピュータプログラム |
| JP7508286B2 (ja) * | 2019-06-25 | 2024-07-01 | キヤノンメディカルシステムズ株式会社 | 検体中の検出対象を検出又は定量する方法、複合粒子、および試薬 |
| US11899013B2 (en) | 2019-06-25 | 2024-02-13 | Canon Medical Systems Corporation | Method of detecting or quantifying detection target in specimen, composite particle, and reagent |
| RU2727779C1 (ru) * | 2019-10-14 | 2020-07-23 | Федеральное государственное казенное военное образовательное учреждение высшего образования "ВОЕННАЯ АКАДЕМИЯ МАТЕРИАЛЬНО-ТЕХНИЧЕСКОГО ОБЕСПЕЧЕНИЯ имени генерала армии А.В. Хрулева" | Двойной интерференционный спектрометр |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1384399A (en) * | 1971-02-01 | 1975-02-19 | Hoffmann La Roche | Automated method of obtaining serological data |
| US3984533A (en) * | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4011044A (en) * | 1976-07-06 | 1977-03-08 | General Electric Company | Use of laser speckle patterns for measurement of electrophoretic mobilities |
-
1976
- 1976-08-16 JP JP51097158A patent/JPS5811575B2/ja not_active Expired
-
1977
- 1977-08-15 CS CS775349A patent/CS221270B2/cs unknown
- 1977-08-16 NL NLAANVRAGE7709039,A patent/NL184027C/xx not_active IP Right Cessation
- 1977-08-16 SE SE7709232A patent/SE445494B/xx not_active IP Right Cessation
- 1977-08-16 GB GB34417/77A patent/GB1545991A/en not_active Expired
- 1977-08-16 BE BE180206A patent/BE857826A/xx not_active IP Right Cessation
- 1977-08-16 FR FR7725049A patent/FR2362398A1/fr active Granted
- 1977-08-16 CH CH999177A patent/CH633370A5/de not_active IP Right Cessation
- 1977-08-16 CA CA284,747A patent/CA1098822A/en not_active Expired
- 1977-08-16 DD DD7700200593A patent/DD132149A5/xx unknown
- 1977-08-16 DE DE2736805A patent/DE2736805C2/de not_active Expired
- 1977-08-16 US US05/825,160 patent/US4118192A/en not_active Expired - Lifetime
- 1977-08-16 HU HU77MI622A patent/HU176294B/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2362398B1 (en:Method) | 1980-07-11 |
| CS221270B2 (en) | 1983-04-29 |
| US4118192A (en) | 1978-10-03 |
| FR2362398A1 (fr) | 1978-03-17 |
| DD132149A5 (de) | 1978-08-30 |
| DE2736805A1 (de) | 1978-02-23 |
| NL184027C (nl) | 1989-03-16 |
| CA1098822A (en) | 1981-04-07 |
| HU176294B (en) | 1981-01-28 |
| SE7709232L (sv) | 1978-02-17 |
| GB1545991A (en) | 1979-05-16 |
| BE857826A (fr) | 1978-02-16 |
| DE2736805C2 (de) | 1982-11-18 |
| NL184027B (nl) | 1988-10-17 |
| JPS5811575B2 (ja) | 1983-03-03 |
| SE445494B (sv) | 1986-06-23 |
| JPS5324015A (en) | 1978-03-06 |
| NL7709039A (nl) | 1978-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2736805C2 (de) | Verfahren zur Bestimmung von Antigenen und Antikörpern | |
| DE2905435C2 (de) | Verfahren und Vorrichtung zur Bestimmung von Antigenen und Antikörpern | |
| DE3685600T2 (de) | Stabilisierte fluoreszierende seltenerd-indikatoren und physiologisch-reaktive kennsatz-spezies. | |
| DE3852117T2 (de) | Immunoassay mit Verwendung von nichtmetallischen, kolloidalen Teilchen. | |
| DE3883351T2 (de) | Latex-Agglutinations-Immuntest in Gegenwart von Hämoglobin. | |
| DE68911674T2 (de) | Testverfahren und reagenzsatz dazu. | |
| US4208185A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| DE3781335T2 (de) | Immunoassay mit verwendung von kolloidalem gold. | |
| DE3887491T2 (de) | Chromatographische Bindungstesteinrichtungen und Verfahren. | |
| DE2905433C2 (de) | Verfahren zur Bestimmung von Antigenen und Antikörpern | |
| DE69125992T2 (de) | Verfahren und Kit für Immunoassay | |
| DE3872621T2 (de) | Nachweis von umgebenden konzentrationen mehrerer analyten. | |
| DE69734266T2 (de) | Immunoassay-Verfahren | |
| EP0407904B1 (de) | Verfahren zur Bestimmung eines Analyten | |
| DE3021208C2 (de) | Verfahren zur Bestimmung eines Antigens, Antikörpers oder Antigen-Antikörperkomplexes und Verwendung eines in einer Verpackungseinheit konfektionierten Mittels zur Durchführung des Verfahrens | |
| CH630465A5 (de) | Verfahren zum nachweis oder zur bestimmung eines antikoerper/antigen-komplexes in einer fluidprobe. | |
| US4203724A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| DE3002973C2 (en:Method) | ||
| DE69106002T2 (de) | Testverfahren und reagenziensatz dafür. | |
| DD202178A5 (de) | Verfahren und reagens zur untersuchung von antigen-antikoerper-reaktionen | |
| DE2804657A1 (de) | Verfahren und vorrichtung zur durchfuehrung von immuntests | |
| EP0253254A2 (de) | Dispersionspolymere, biologisch aktive Dispersionspolymere, Verfahren zu ihrer Herstellung und Verwendung als diagnostisches Mittel | |
| DE3787706T2 (de) | Verfahren zur quantitativen Bestimmung der Antigene und Antikörper. | |
| DE2754645C2 (de) | Verfahren zum Nachweis und zur Bestimmung von Antigenen oder Antikörpern in Flüssigkeiten | |
| DE69021159T2 (de) | Verfahren zum immunochemischen Bestimmen von Haptenen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: MITSUBISHI KASEI CORPORATION |
|
| PL | Patent ceased |